Check-Cap is a clinical stage medical diagnostics company. Co. has introduced the C-Scan® test designed to detect polyps before they transform into cancer. The disruptive capsule-based screening technology utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities. Co.'s C-Scan system is comprised of three main components: C-Scan Cap, an ingestible X-ray scanning capsule; C-Scan Track, three miniaturized patches worn on the patient's back for integrated positioning, control and data recording; and C-Scan View, a proprietary software to process and represent 2D and 3D maps of the inner surface of the colon. The CHEK average annual return since 2015 is shown above.
The Average Annual Return on the CHEK average annual return since 2015 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether CHEK average annual return since 2015 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the CHEK average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free CHEK Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
